Publications by authors named "Kai Hove"
Article Synopsis
- CAB + RPV LA is an HIV-1 treatment regimen given every 2 months that was evaluated in the CARISEL study for its effectiveness and patient outcomes after 12 months.
- The study involved 430 patients who switched from daily oral therapy to this long-acting treatment, and the majority maintained low viral loads, with only a small percentage showing signs of treatment failure.
- Overall, CAB + RPV LA was found to be safe, well-tolerated, and effective in keeping patients' HIV levels suppressed.
Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
Cassidy A Gutner Laurent Hocqueloux Celia Jonsson-Oldenbüttel Linos Vandekerckhove Berend J van Welzen Kai Hove
J Int AIDS Soc
July 2024
Article Synopsis
- Cabotegravir plus rilpivirine (CAB+RPV) is a long-acting HIV treatment being studied for its implementation effectiveness in European clinics through the CARISEL study.
- The study involved 18 clinics that were divided into two groups: one received standard support, while the other got enhanced support that included more training and team meetings.
- Staff participants (SSPs) reported high acceptability, appropriateness, and feasibility scores for CAB+RPV throughout the year, indicating positive feedback on its implementation, with no significant differences noted between the two support groups.
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study, demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long-acting dosed every 4 weeks was noninferior at week (W) 48 to continuing three-drug daily oral current antiretroviral therapy (CAR). Results from the W 96 analysis are presented.
Methods And Design: Participants completing W 52 of ATLAS were given the option to withdraw, transition to ATLAS-2M (NCT03299049), or enter an Extension Phase to continue long-acting therapy (Long-acting arm) or switch from CAR to long-acting therapy (Switch arm).